Aytu BioPharma, Inc. (Nasdaq: AYTU) reported its financial results for fiscal year 2026 and the fourth quarter ended June 30, 2026. The company announced that net revenue for the fourth quarter of fiscal 2026 was $16.1 million, representing a 6.4% increase compared to the prior-year quarter of $15.1 million. For the full fiscal year 2026, total net revenue decreased 13.3% to $57.6 million from $66.4 million in fiscal 2025.
The company highlighted the commercial launch of its EXXUA product, which is indicated for major depressive disorder. EXXUA generated $3.9 million in net revenue during the fourth quarter of fiscal 2026, marking the first full quarter of commercial availability. The product was made commercially available in mid-December 2025, with a formal launch occurring in mid-January 2026. EXXUA accounted for $6.6 million of total net revenue for the full fiscal year 2026.
Conversely, revenue from the company's legacy portfolios declined. The ADHD Portfolio, which includes products like Adzenys, saw net revenue drop to $10.4 million in the fourth quarter from $13.1 million in the prior year, and to $45.8 million for the full year from $57.6 million. The Pediatric Portfolio also saw a decrease, falling to $1.8 million in the fourth quarter from $2.0 million and $5.1 million for the full year from $8.8 million. The company attributed these declines to commercial prioritization of EXXUA and the introduction of generic competition.
On the income statement, Aytu BioPharma reported a net loss of approximately break-even, or less than ($0.1) million, in the fourth quarter of fiscal 2026. This compares to a net loss of ($19.8) million in the prior year quarter. For the full fiscal year 2026, the company reported a net loss of ($14.3) million, or ($1.16) per share, compared to a net loss of ($13.6) million, or ($2.16) per share, in fiscal 2025. Adjusted EBITDA for the fourth quarter was $0.5 million, while full-year Adjusted EBITDA was ($3.7) million.
As of June 30, 2026, the company held $26.3 million in cash and cash equivalents. Management noted that the company made planned investments toward the commercialization of EXXUA during the period. The company will host a conference call and webcast today, September 22, 2026, at 4:30 p.m. Eastern time to discuss these results.
